182 related articles for article (PubMed ID: 15505370)
1. The potential role of tau protein O-glycosylation in Alzheimer's disease.
Robertson LA; Moya KL; Breen KC
J Alzheimers Dis; 2004 Oct; 6(5):489-95. PubMed ID: 15505370
[TBL] [Abstract][Full Text] [Related]
2. Prediction of human tau 3D structure, and interplay between O-β-GlcNAc and phosphorylation modifications in Alzheimer's disease: C. elegans as a suitable model to study these interactions in vivo.
Ahmad W; Shabbiri K; Ahmad I
Biochem Biophys Res Commun; 2020 Jul; 528(3):466-472. PubMed ID: 32499112
[TBL] [Abstract][Full Text] [Related]
3. Reduction of O-linked N-acetylglucosamine-modified assembly protein-3 in Alzheimer's disease.
Yao PJ; Coleman PD
J Neurosci; 1998 Apr; 18(7):2399-411. PubMed ID: 9502801
[TBL] [Abstract][Full Text] [Related]
4. Evidence for an imbalance between tau O-GlcNAcylation and phosphorylation in the hippocampus of a mouse model of Alzheimer's disease.
Gatta E; Lefebvre T; Gaetani S; dos Santos M; Marrocco J; Mir AM; Cassano T; Maccari S; Nicoletti F; Mairesse J
Pharmacol Res; 2016 Mar; 105():186-97. PubMed ID: 26816085
[TBL] [Abstract][Full Text] [Related]
5. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.
Liu F; Iqbal K; Grundke-Iqbal I; Hart GW; Gong CX
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10804-9. PubMed ID: 15249677
[TBL] [Abstract][Full Text] [Related]
6. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.
Buerger K; Ewers M; Pirttilä T; Zinkowski R; Alafuzoff I; Teipel SJ; DeBernardis J; Kerkman D; McCulloch C; Soininen H; Hampel H
Brain; 2006 Nov; 129(Pt 11):3035-41. PubMed ID: 17012293
[TBL] [Abstract][Full Text] [Related]
7. The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer's Disease.
Dugger BN; Whiteside CM; Maarouf CL; Walker DG; Beach TG; Sue LI; Garcia A; Dunckley T; Meechoovet B; Reiman EM; Roher AE
J Alzheimers Dis; 2016; 51(2):345-56. PubMed ID: 26890756
[TBL] [Abstract][Full Text] [Related]
8. Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins--a role in nuclear localization.
Lefebvre T; Ferreira S; Dupont-Wallois L; Bussière T; Dupire MJ; Delacourte A; Michalski JC; Caillet-Boudin ML
Biochim Biophys Acta; 2003 Jan; 1619(2):167-76. PubMed ID: 12527113
[TBL] [Abstract][Full Text] [Related]
9. Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease.
Wang JZ; Grundke-Iqbal I; Iqbal K
Nat Med; 1996 Aug; 2(8):871-5. PubMed ID: 8705855
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimer's disease.
Iqbal K; Grundke-Iqbal I
Mol Neurobiol; 1991; 5(2-4):399-410. PubMed ID: 1726645
[TBL] [Abstract][Full Text] [Related]
11. Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation.
Smet-Nocca C; Broncel M; Wieruszeski JM; Tokarski C; Hanoulle X; Leroy A; Landrieu I; Rolando C; Lippens G; Hackenberger CP
Mol Biosyst; 2011 May; 7(5):1420-9. PubMed ID: 21327254
[TBL] [Abstract][Full Text] [Related]
12. Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease.
Liu F; Zaidi T; Iqbal K; Grundke-Iqbal I; Merkle RK; Gong CX
FEBS Lett; 2002 Feb; 512(1-3):101-6. PubMed ID: 11852060
[TBL] [Abstract][Full Text] [Related]
13. Immunoreactivity patterns in neurofibrillary tangles of the inferior temporal cortex in Alzheimer disease.
Duong T; Gallagher KA
Mol Chem Neuropathol; 1994 Jun; 22(2):105-22. PubMed ID: 7916770
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and molecular characterization of neurofibrillary degeneration in frontotemporal dementias.
Delacourte A
Dement Geriatr Cogn Disord; 1999; 10 Suppl 1():75-9. PubMed ID: 10436346
[TBL] [Abstract][Full Text] [Related]
15. Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities.
Koppel J; Acker C; Davies P; Lopez OL; Jimenez H; Azose M; Greenwald BS; Murray PS; Kirkwood CM; Kofler J; Sweet RA
Neurobiol Aging; 2014 Sep; 35(9):2021-8. PubMed ID: 24731519
[TBL] [Abstract][Full Text] [Related]
16. Does O-GlcNAc play a role in neurodegenerative diseases?
Lefebvre T; Guinez C; Dehennaut V; Beseme-Dekeyser O; Morelle W; Michalski JC
Expert Rev Proteomics; 2005 Apr; 2(2):265-75. PubMed ID: 15892570
[TBL] [Abstract][Full Text] [Related]
17. miR-106b inhibits tau phosphorylation at Tyr18 by targeting Fyn in a model of Alzheimer's disease.
Liu W; Zhao J; Lu G
Biochem Biophys Res Commun; 2016 Sep; 478(2):852-7. PubMed ID: 27520374
[TBL] [Abstract][Full Text] [Related]
18. Tau therapeutic strategies for the treatment of Alzheimer's disease.
Churcher I
Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
[TBL] [Abstract][Full Text] [Related]
19. Altered glycosylation pattern of proteins in Alzheimer disease.
Guevara J; Espinosa B; Zenteno E; Vázguez L; Luna J; Perry G; Mena R
J Neuropathol Exp Neurol; 1998 Oct; 57(10):905-14. PubMed ID: 9786241
[TBL] [Abstract][Full Text] [Related]
20. Isoprenoids and tau pathology in sporadic Alzheimer's disease.
Pelleieux S; Picard C; Lamarre-Théroux L; Dea D; Leduc V; Tsantrizos YS; Poirier J
Neurobiol Aging; 2018 May; 65():132-139. PubMed ID: 29476987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
